SVRA

Savara Inc. (SVRA) - Q2 2024 10-Q Summary

Business Context and Reporting Period

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole product candidate is molgramostim, an inhaled biologic in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The company has no commercial revenue and operates in a single segment. This report covers the quarterly period ended June 30, 2024.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no product revenue.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose 89.8% year-over-year for the six months ended June 30, 2024, from $24.3 million to $45.7 million.
• R&D Surge: Research and development expenses increased 95.0% to $34.4 million (YTD 2024) compared to $17.6 million in the prior year period. This was driven by chemistry, manufacturing, and controls (CMC) activities ($9.2 million), clinical trial costs for IMPALA-2 and a new Pediatric Study ($2.1 million), and increased personnel costs ($3.6 million).
• G&A Growth: General and administrative expenses increased 67.6% to $11.2 million (YTD 2024), attributed to personnel costs, commercial preparation activities, and patient advocacy.
• Net Loss Expansion: Net loss for the six months ended June 30, 2024, was $42.6 million, compared to $22.0 million in the same period in 2023.
• Investment Activity: Net cash provided by investing activities was $40.3 million, primarily due to the maturity of short-term investments ($74.5 million) partially offset by new purchases ($34.1 million).

Outlook, Risks, and Subsequent Events

• Subsequent Financing: On July 1, 2024, Savara completed a registered direct offering of 26.2 million shares at $3.81 per share, generating gross proceeds of approximately $100.0 million (estimated net proceeds of $93.7 million).
• Liquidity Position: Management states that cash, cash equivalents, and short-term investments as of June 30, 2024, are sufficient to fund operations for at least the next twelve months, excluding the proceeds from the July 2024 offering.
• Debt Covenants: The company has a $26.5 million term loan with Silicon Valley Bank. It is currently in an interest-only period through April 2026. Covenants require maintaining cash balances relative to operating expenses and debt principal.
• Risks: Key risks include the failure to obtain regulatory approval for molgramostim, the need for additional capital to fund development and commercialization, and the uncertainty of clinical trial outcomes. The company has incurred operating losses since inception and expects to continue doing so.
• Commitments: The company has contingent milestone payments of approximately $1.8 million related to manufacturing and regulatory approvals, plus an estimated $20.0 million obligation to a second-source manufacturer and $42.5 million for clinical trial services with Parexel.

Investor Verification Checklist

• Cash Runway: Verify the impact of the July 2024 offering on the total cash runway and whether it extends the funding horizon beyond the 12-month estimate provided in the filing.
• CMC Costs: Confirm the timeline and cost implications of establishing the second drug substance manufacturer, which drove a significant portion of Q2 R&D spend.
• Clinical Milestones: Monitor enrollment progress and data readouts for the IMPALA-2 Phase 3 trial and the newly initiated Pediatric Study.
• Debt Compliance: Review future quarterly reports to ensure compliance with the cash balance covenants tied to the Silicon Valley Bank term loan.
• Dilution: Assess the dilution impact of the recent $100 million equity raise and the existing pool of warrants and options (approx. 57.8 million shares reserved).